摘要
目的对比分析碘[^(131)I]美妥昔单抗注射液与肝动脉化疗栓塞术(transcatheter arterial chemoembolization,TACE)治疗原发性肝癌(primary liver cancer,PLC)的临床疗效。方法根据治疗方法的不同将PLC患者分为TACE组(n=31)和碘[^(131)I]美妥昔单抗组(n=32)。TACE组行TACE治疗,碘[^(131)I]美妥昔单抗组经肝动脉途径灌注碘[^(131)I]美妥昔单抗注射液,治疗3个月后对两组甲胎蛋白(AFP)转阴率、肿瘤缩小率及生存期进行比较,并观察不良反应发生情况,随访至2015年8月。结果治疗3个月后,碘[^(131)I]美妥昔单抗组AFP转阴率及肿瘤缩小率略高于TACE组,但差异无统计学意义(P>0.05);治疗期间两组均无明显不良反应;截止到随访结束,TACE组生存率为19.4%(6/31),碘[^(131)I]美妥昔单抗组为43.8%(14/32),碘[^(131)I]美妥昔单抗组生存率高于TACE组,且差异有统计学意义(P<0.05)。结论对于PLC的治疗,碘[^(131)I]美妥昔单抗注射液在提高AFP转阴率、肿瘤缩小率及生存率方面优于TACE。
Objective To compare the efficacy of Iodine[131^I]Metuximab Injection and transcatheter arterial chemoembolization（TACE）in the treatment of primary liver cancer（PLC）.Methods According to different treatment methods,the patients with PLC were divided into TACE group（n=31）and iodine[131^I]metuximab monoclonal antibody（mAb）group（n=32）.The patients in TACE group received TACE,while those in iodine[131^I]metuximab mAb group were perfused with Iodine[131^I]Metuximab Injection via hepatic artery.The rate of negative conversion of alpha fetoprotein（AFP）and tumor regression rate 3 months after treatment as well as survival rate were compared between two groups,and adverse reactions were observed closely.All patients were followed up until August,2015.Results 3 months after treatment,both negative conversion rate of AFP and tumor regression rate in iodine[131^I]metuximab mAb group were slightly higher than those in TACE group,but no statistically significant difference was presented（P〉0.05）.Until the end of follow-up,the survival rate of TACE group was 19.4%（6/31）,which was markedly lower than the 43.8%（14/32）in iodine[131^I]metuximab mAb group（P〈0.05）.Conclusion For PLC,the efficacy of Iodine[131 I]Metuximab Injection is superior to TACE in improving tumor regression rate,negative conversion rate of AFP and survival rate.
出处
《成都医学院学报》
CAS
2015年第6期649-651,656,共4页
Journal of Chengdu Medical College
基金
山东省科技发展计划支持项目(No:2013YD18013)
中国高校医学期刊临床专项资金(No:11521565)
关键词
碘[131^I]美妥昔单抗
肝动脉化疗栓塞术
原发性肝癌
甲胎蛋白
Iodine[131^I] Metuximab Injection
Transcatheter arterial chemoembolization
Primary liver cancer
Alpha fetoprotein
